Systemic Mast Cell Activation

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Blueprint Medicines
Blueprint MedicinesMA - Cambridge
1 program
ScreeningN/A1 trial
Active Trials
NCT04811365Completed379Est. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Blueprint MedicinesScreening

Clinical Trials (1)

Total enrollment: 379 patients across 1 trials

NCT04811365Blueprint MedicinesScreening

(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation

Start: Jun 2021Est. completion: Mar 2023379 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space